Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Research & Development: 2022-2025

Historic Research & Development for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to $25.7 million.

  • Taysha Gene Therapies' Research & Development rose 72.25% to $25.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.8 million, marking a year-over-year increase of 21.18%. This contributed to the annual value of $66.0 million for FY2024, which is 16.24% up from last year.
  • According to the latest figures from Q3 2025, Taysha Gene Therapies' Research & Development is $25.7 million, which was up 27.82% from $20.1 million recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Research & Development ranged from a high of $38.2 million in Q1 2022 and a low of $11.8 million during Q3 2023.
  • In the last 3 years, Taysha Gene Therapies' Research & Development had a median value of $15.3 million in 2024 and averaged $16.7 million.
  • In the last 5 years, Taysha Gene Therapies' Research & Development tumbled by 67.23% in 2023 and then soared by 72.25% in 2025.
  • Taysha Gene Therapies' Research & Development (Quarterly) stood at $12.7 million in 2022, then fell by 0.20% to $12.7 million in 2023, then climbed by 20.84% to $15.3 million in 2024, then skyrocketed by 72.25% to $25.7 million in 2025.
  • Its last three reported values are $25.7 million in Q3 2025, $20.1 million for Q2 2025, and $15.6 million during Q1 2025.